<DOC>
	<DOCNO>NCT00261508</DOCNO>
	<brief_summary>The purpose study evaluate effectiveness oral solution risperidone ( antipsychotic medication ) versus placebo treatment behavioral symptom child Pervasive Developmental Disorders ( PDD ) .</brief_summary>
	<brief_title>A Study Effectiveness Safety Risperidone Versus Placebo Treatment Children With Autistic Disorder Other Pervasive Developmental Disorders ( PDD )</brief_title>
	<detailed_description>The Pervasive Developmental Disorders ( PDD ) group neuropsychiatric disorder , include autistic disorder , characterize specific delay deviance social , communicative , cognitive development onset typically first year life . Children PDD may show multiple , serious symptom include hyperactivity , inattention , impulsive aggressive behavior , repetitive movement speech pattern , sleep disorder , scream , self-injurious behavior . Drug study date suggest different behavioral symptom PDDs respond neuroleptic , risperidone . This randomized , double-blind , placebo-controlled study evaluate effectiveness risperidone ( 0.02 0.06 mg/kg/day ) compare placebo treatment behavioral symptom child 5 12 year age Pervasive Developmental Disorders ( PDD ) . Patients receive study medication ( risperidone placebo ) take orally day gradually increase dos maximum 0.06 mg/kg , adjust weekly interval achieve optimal effectiveness minimize intolerance drug . Treatment continue optimal dose Week 8 . A parent caregiver evaluate child 's behavior symptom schedule office visit course treatment . The primary measure effectiveness change Irritability Subscale Aberrant Behavior Checklist ( ABC ) ABC subscales end treatment compare baseline . Additional assessment effectiveness include : Nisonger Child Behavior Rating Form ( N-CBRF ) ; Visual Analogue Scale ( VAS ) , measure patient 's disturbing symptom ; Clinical Global Impression ( CGI ) overall severity disorder . Safety assessment include incidence adverse event throughout study ; measurement vital sign ( pulse , temperature , blood pressure ) , body weight , evaluation presence severity extrapyramidal symptom Extrapyramidal Symptom Rating Scale ( ESRS ) specify interval ; clinical laboratory test ( hematology , biochemistry , urinalysis ) study initiation end treatment . The study hypothesis risperidone effective placebo treatment behavioral symptom child age 5 12 year Pervasive Developmental Disorders ( PDD ) . Risperidone oral solution 1 mg/mL placebo , take orally , daily . Days 1 - 2 , dose 0.01 mg/kg body weight . Days 3 - 7 dose 0.02 mg/kg , increase Days 8 - 14 0.04 mg/kg ( maximum ) , 0.06 mg/kg ( maximum ) 8 week . Dosage may adjust investigator 's discretion .</detailed_description>
	<mesh_term>Disease</mesh_term>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Autistic Disorder</mesh_term>
	<mesh_term>Rett Syndrome</mesh_term>
	<mesh_term>Autism Spectrum Disorder</mesh_term>
	<mesh_term>Child Development Disorders , Pervasive</mesh_term>
	<mesh_term>Developmental Disabilities</mesh_term>
	<mesh_term>Asperger Syndrome</mesh_term>
	<mesh_term>Risperidone</mesh_term>
	<criteria>Diagnosis Pervasive Developmental Disorders ( Autistic Disorder , Rett 's Disorder , Childhood Disintegrative Disorder , Asperger 's Disorder , Pervasive Development Disorder Otherwise Specified ) Diagnostic Statistical Manual Mental Disorders , 4th edition ( DSMIV ) , Axis I criteria total score &gt; =30 Childhood Autism Rating Scale ( CARS ) receive treatment outpatient healthy basis physical examination , electrocardiogram ( ECG ) , medical history start study . Diagnosis schizophrenia psychotic disorder DSMIV criterion seizure 3 month prior study initiation currently treat one anticonvulsant drug history tardive dyskinesia ( complication neuroleptic therapy involve involuntary movement facial muscle ) neuroleptic malignant syndrome ( rare psychotropicdrug reaction , may characterize confusion , reduce consciousness , high fever pronounce muscle stiffness ) know hypersensitivity , intolerance , unresponsiveness risperidone .</criteria>
	<gender>All</gender>
	<minimum_age>5 Years</minimum_age>
	<maximum_age>12 Years</maximum_age>
	<verification_date>January 2011</verification_date>
	<keyword>Risperidone</keyword>
	<keyword>child development disorder</keyword>
	<keyword>pervasive development disorder</keyword>
	<keyword>autistic disorder</keyword>
	<keyword>autism</keyword>
	<keyword>developmental disability</keyword>
	<keyword>antipsychotropic agent</keyword>
</DOC>